IGC PHARMA INC (IGC)
US45408X3089 - Common Stock
We assign a fundamental rating of 2 out of 10 to IGC. IGC was compared to 198 industry peers in the Pharmaceuticals industry. IGC may be in some trouble as it scores bad on both profitability and health. IGC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IGC has reported negative net income.
In the past year IGC has reported a negative cash flow from operations.
IGC had negative earnings in each of the past 5 years.
In the past 5 years IGC always reported negative operating cash flow.
1.2 Ratios
IGC's Return On Assets of -125.67% is on the low side compared to the rest of the industry. IGC is outperformed by 86.15% of its industry peers.
Looking at the Return On Equity, with a value of -156.29%, IGC is doing worse than 69.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.67% | ||
| ROE | -156.29% | ||
| ROIC | N/A |
ROA(3y)-49.18%
ROA(5y)-36.94%
ROE(3y)-55.64%
ROE(5y)-41.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IGC has a better Gross Margin (50.90%) than 62.05% of its industry peers.
In the last couple of years the Gross Margin of IGC has grown nicely.
The Profit Margin and Operating Margin are not available for IGC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y154.06%
GM growth 5Y67.63%
2. Health
2.1 Basic Checks
IGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
IGC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IGC has more shares outstanding
Compared to 1 year ago, IGC has a worse debt to assets ratio.
2.2 Solvency
IGC has an Altman-Z score of -8.80. This is a bad value and indicates that IGC is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IGC (-8.80) is worse than 72.82% of its industry peers.
IGC has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
IGC's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. IGC outperforms 54.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.8 |
ROIC/WACCN/A
WACC9.26%
2.3 Liquidity
A Current Ratio of 1.85 indicates that IGC should not have too much problems paying its short term obligations.
IGC has a Current ratio of 1.85. This is in the lower half of the industry: IGC underperforms 68.21% of its industry peers.
IGC has a Quick Ratio of 1.85. This is a bad value and indicates that IGC is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.86, IGC is doing worse than 84.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 0.86 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.56% over the past year.
Looking at the last year, IGC shows a very strong growth in Revenue. The Revenue has grown by 42.33%.
The Revenue for IGC have been decreasing by -16.11% on average. This is quite bad
EPS 1Y (TTM)4.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-119.25%
Revenue 1Y (TTM)42.33%
Revenue growth 3Y-39.31%
Revenue growth 5Y-16.11%
Revenue growth Q2Q-38.18%
3.2 Future
IGC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.49% yearly.
The Revenue is expected to grow by 24.61% on average over the next years. This is a very strong growth
EPS Next Y-1%
EPS Next 2Y12.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year37.91%
Revenue Next 2Y24.61%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IGC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IGC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IGC's earnings are expected to grow with 12.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.49%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IGC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IGC PHARMA INC
NYSEARCA:IGC (4/26/2024, 12:42:44 PM)
0.445
+0.02 (+3.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap29.61M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -125.67% | ||
| ROE | -156.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 50.9% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.85 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)4.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-1%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)42.33%
Revenue growth 3Y-39.31%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y